Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Wall Street Analyst Weigh In
PEN has been the topic of a number of research reports. William Blair reissued an "outperform" rating on shares of Penumbra in a research note on Tuesday, May 3rd. TheStreet cut Penumbra from a "c-" rating to a "d+" rating in a report on Tuesday, July 12th. Truist Financial decreased their target price on Penumbra to $180.00 in a report on Friday, July 22nd. BTIG Research decreased their target price on Penumbra from $272.00 to $213.00 and set a "buy" rating on the stock in a report on Monday, July 18th. Finally, Canaccord Genuity Group decreased their target price on Penumbra from $244.00 to $189.00 and set a "buy" rating on the stock in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $218.78.
Penumbra Stock Down 0.6 %
Shares of PEN Stock traded down $1.01 on Friday, reaching $167.19. 165,915 shares of the company's stock traded hands, compared to its average volume of 439,108. Penumbra has a 12-month low of $114.86 and a 12-month high of $293.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 4.93. The company has a market capitalization of $6.33 billion, a P/E ratio of -321.51 and a beta of 0.73. The business's 50 day moving average price is $136.91 and its two-hundred day moving average price is $171.76.
Penumbra (NYSE:PEN - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. Penumbra had a positive return on equity of 0.97% and a negative net margin of 2.40%. The business had revenue of $208.30 million for the quarter, compared to the consensus estimate of $206.24 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. Penumbra's revenue for the quarter was up 13.0% compared to the same quarter last year. On average, equities analysts forecast that Penumbra will post 0.25 earnings per share for the current year.
Insider Buying and Selling at Penumbra
In other Penumbra news, Director Thomas Wilder sold 248 shares of the business's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $123.64, for a total value of $30,662.72. Following the transaction, the director now owns 462 shares in the company, valued at $57,121.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Penumbra news, Director Thomas Wilder sold 248 shares of the business's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $123.64, for a total value of $30,662.72. Following the completion of the sale, the director now owns 462 shares of the company's stock, valued at $57,121.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Johanna Roberts sold 1,700 shares of the business's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $175.04, for a total value of $297,568.00. Following the completion of the sale, the executive vice president now directly owns 55,496 shares of the company's stock, valued at approximately $9,714,019.84. The disclosure for this sale can be found here. Insiders have sold 2,151 shares of company stock worth $355,536 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.
